|
|
| (3 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| − | There doesn't seem to be a standard rule on this, although apparently independent monitoring boards can make the decision if they see fit. A drug could take up to 10, 15 years or more to complete all 3 phases of its clinical trial, but this time varies depending on factors such as the type of treatment and problems with the new drug. <ref> Cancer Research UK [[http://www.cancerhelp.org.uk/help/default.asp?page=14656]] Accessed on December, 6, 2008.</ref>
| |
| | | | |
| − |
| |
| − | Is this the best way to ensure the safety and efficacy of patients, the two most important duties of the [[MHRA]]'s expert advisory body, the [[Commission on Human Medicine]]? A member of the [[British Pharmacopoeia Commission]], who prefers to remain anonymous,had this to say about the recent controversy surrounding [[Vioxx]]:
| |
| − |
| |
| − |
| |
| − | :'The adverse reaction with Vioxx only became effective after 18 months and the risk was an increased cardiovascular event. Slightly. A slight but real risk, but this wasn’t showing up if a patient was taking it for 18 months. Ie. If a patient was only taking it for 12 months, it only became apparent after 18 months. There's a very fine balance, you have the experts, the scientific experts as employees of the [[MHRA]] and those employed on commissions to advise of the work of the MHRA – they only take decisions based on information they receive.'
| |
| − |
| |
| − |
| |
| − | So why not gather as much information as possible before making a decision that could harm patients? This may have made a difference during the clinical trials for the anti-cholesterol drug [[Crestor]] ([[Rosuvastatin]]). There have been calls to have it removed from the market due to safety concerns as it carries a higher risk of side effects compared to other statins. http://news.bbc.co.uk/1/hi/health/3838915.stm
| |
| − |
| |
| − | But these negative reports have been buried under a barrage of good news. It has now emerged the statin drug trial was halted six months early after being hailed a success.
| |
| − |
| |
| − | von Radovitz, J.[http://www.independent.co.uk/life-style/health-and-wellbeing/health-news/statin-drug-trial-halted-six-months-early-after-success-1006623.html Statin Drug Trial Halted Six Months Early After Success] ''The Independent'' Accessed on December,1,2008
| |
| − |
| |
| − | 'The study was funded by the drug company Astra-Zeneca, the maker of the statin used in the trial, rosuvastatin, marketed under the name Crestor. Astra-Zeneca had no access to unblinded trial data and played no role in the study’s analysis or interpretation, according to Brigham and Women’s Hospital.' http://www.physorg.com/news145450584.html
| |
